Subcutaneous Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis

References

• Marelli L, Romano M, Pontikaki I, et al. Long term experience in patients with JIA-associated uveitis in a large referral center. Front Pediatr. 2021;9:682327. doi:10.3389/fped.2021.682327.
   PubMed Web of Science ®Google Scholar
• Calvo-Río V, Santos-Gómez M, Calvo I, et al. Anti-interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients. Arthritis Rheumatol. 2017;69(3):668–675. doi:10.1002/art.39940.
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Mesquida M, Adán A, et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2016;43(12):2183–2188. doi:10.3899/jrheum.160231.
   PubMed Web of Science ®Google Scholar
• Maleki A, Manhapra A, Asgari S, Chang PY, Foster CS, Anesi SD. Tocilizumab employment in the treatment of resistant juvenile idiopathic arthritis associated uveitis. Ocul Immunol Inflamm. 2021;29(1):14–20. doi:10.1080/09273948.2020.1817501.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Modorati G, Berchicci L, Pontikaki I, Meroni P, Gerloni V. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol. 2016;100(6):782–786. doi:10.1136/bjophthalmol-2015-306790.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Giuffrè C, Cornalba M, Pontikaki I, Cimaz R. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol. 2020;39(3):847–851. doi:10.1007/s10067-019-04875-w.
   PubMed Web of Science ®Google Scholar
• Cimaz R, Marino A, Martini A. How I treat juvenile idiopathic arthritis: a state of the art review. Autoimmun Rev. 2017;16(10):1008–1015. doi:10.1016/j.autrev.2017.07.014.
   PubMed Web of Science ®Google Scholar
• Sepah YJ, Sadiq MA, Chu DS, et al. Primary (Month-6) outcomes of the STOP-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis. Am J Ophthalmol. 2017;183:71–80. doi:10.1016/j.ajo.2017.08.019.
   PubMed Web of Science ®Google Scholar
• Mesquida M, Molins B, Llorenç V, et al. Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema. Retina. 2018;38(7):1361–1370. doi:10.1097/IAE.0000000000001690.
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Dick AD, Guly C, et al. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. Lancet Rheumatol. 2020;2(3):e135–e141. doi:10.1016/S2665-9913(20)30008-4.
   PubMedGoogle Scholar
• Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–392.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–516. doi:10.1016/j.ajo.2005.03.057.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Massa M, Pignatti P, Albani S, Novick D, Martini A. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest. 1994;93(5):2114–2119. doi:10.1172/JCI117206.
   PubMed Web of Science ®Google Scholar
• Perez VL, Papaliodis GN, Chu D, Anzaar F, Christen W, Foster CS. Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies. Ocul Immunol Inflamm. 2004;12(3):193–201. doi:10.1080/092739490500282.
   PubMed Web of Science ®Google Scholar
• Kramer M, Monselise Y, Bahar I, Cohen Y, Weinberger D, Goldenberg-Cohen N. Serum cytokine levels in active uveitis and remission. Curr Eye Res. 2007;32(7–8):669–675. doi:10.1080/02713680701523147.
   PubMed Web of Science ®Google Scholar
• Yoshimura T, Sonoda KH, Ohguro N, et al. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford). 2009;48(4):347–354. doi:10.1093/rheumatology/ken489.
   PubMed Web of Science ®Google Scholar
• Haruta H, Ohguro N, Fujimoto M, et al. Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 2011;52(6):3264–3271. doi:10.1167/iovs.10-6272.
   PubMed Web of Science ®Google Scholar
• Karkhur S, Hasanreisoglu M, Vigil E, et al. Interleukin-6 inhibition in the management of non-infectious uveitis and beyond. J Ophthalmic Inflamm Infect. September 16,2019 9(1):17. doi:10.1186/s12348-019-0182-y.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Rubbert-Roth A, Cantagrel A, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis. 2014;73(1):69–74. doi:10.1136/annrheumdis-2013-203523.
   PubMed Web of Science ®Google Scholar
• Kivitz A, Olech E, Borofsky M, et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66(11):1653–1661. doi:10.1002/acr.22384.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Brunner HI, Ramanan AV, et al. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford). 2021;60(10):4568–4580. doi:10.1093/rheumatology/keab047.
   PubMed Web of Science ®Google Scholar
• Adán A, Moll-Udina A, Ramirez J, Llorenç V. Subcutaneous tocilizumab for cystoid macular edema secondary to Juvenile Idiopathic Arthritis (JIA)-associated uveitis: a case report. Ocul Immunol Inflamm. 2021;29(1):6–8. doi:10.1080/09273948.2019.1644350.
   PubMed Web of Science ®Google Scholar
• Quesada-Masachs E, Caballero CM. Subcutaneous tocilizumab may be less effective than intravenous tocilizumab in the treatment of juvenile idiopathic arthritis-associated uveitis. J Rheumatol. 2017;44:260–261. doi:10.3899/jrheum.160908.
   PubMed Web of Science ®Google Scholar